BIS (Bispectral Index) Monitoring Under Anaesthesia

Introduction

• 100 = fully awake
• 80-100 = light sedation
• 60-80 = moderate sedation
• 40-60 = general anaesthesia (target range for surgical anaesthesia)
• <40 = deep hypnotic state / burst suppression
• 0 = flat EEG (isoelectric/cortical silence)

Principle/Mechanism

• Time domain analysis (burst suppression ratio)
• Frequency domain analysis (power spectrum)
• Bispectral analysis (phase coupling between frequency components)

Indications for BIS Monitoring

1. Prevention/detection of intraoperative awareness (accidental awareness during general anaesthesia, AAGA) - the primary indication, particularly in high-risk patients:
   • History of previous awareness
   • Chronic use of alcohol, opioids, benzodiazepines (higher anaesthetic requirement, tolerance)
   • Anticipated difficult airway/intubation
   • ASA physical status IV-V with limited cardiovascular reserve
   • Cardiac surgery, trauma surgery, obstetric (Caesarean) anaesthesia
   • Total intravenous anaesthesia (TIVA), especially with neuromuscular blockade (where clinical signs of light anaesthesia are masked)
2. Titration of anaesthetic depth - guiding administration of intravenous/inhalational agents to avoid both under-dosing (risk of awareness) and over-dosing (risk of haemodynamic instability, delayed recovery, postoperative cognitive dysfunction).
3. Reduction of anaesthetic drug consumption and faster recovery/"fast-tracking" - BIS-guided titration has been shown to reduce anaesthetic agent use and time to extubation/discharge from PACU in some studies.
4. Sedation monitoring outside the operating room - ICU sedation, procedural sedation (endoscopy, interventional radiology), monitored anaesthesia care.
5. Neuroanaesthesia and cardiac surgery - adjunct for detecting gross changes in cortical function (e.g., cerebral ischaemia, though not sensitive/specific for this).
6. Patients at extremes where standard MAC-based dosing is unreliable - e.g., elderly (to avoid excessive depth and reduce risk of postoperative delirium/cognitive dysfunction), obese patients on TIVA.
7. Detection of excessive anaesthetic depth - avoiding burst suppression, which has been associated with postoperative delirium and possibly increased mortality in some observational studies.

Limitations of BIS Monitoring

1. Does not reliably prevent awareness in all circumstances - large trials (e.g., B-Aware, BAG-RECALL, B-Unaware) showed BIS-guided anaesthesia was not clearly superior to a well-conducted end-tidal anaesthetic gas concentration protocol for preventing awareness in high-risk patients. As noted in Miller's Anesthesia: "Three randomized trials showed BIS helps prevent awareness in high-risk population, but it is not better than an end-tidal anesthetic gas protocol."
2. Drug-specific interference/inaccuracy:
   • Nitrous oxide and ketamine can give falsely high BIS values despite adequate anaesthesia (due to their EEG excitatory effects).
   • Opioids alone have minimal effect on BIS, so BIS does not measure analgesia/nociception - a patient can have a "surgical" BIS value yet respond to painful stimulation (haemodynamically or with movement) because BIS reflects hypnosis, not analgesia.
   • Dexmedetomidine and etomidate can produce inconsistent BIS readings.
3. Electromyographic (EMG) artefact - frontalis muscle activity (from inadequate neuromuscular blockade, shivering, or patient movement) falsely elevates BIS, giving a false impression of light anaesthesia.
4. Electrical interference - diathermy/electrocautery, warming blankets, pacemakers, and other electrical equipment in the OR can distort the signal.
5. Population limitations:
   • Algorithm derived largely from adult EEG data; less validated and less reliable in children, especially infants and neonates, due to immature/different EEG patterns.
   • Less reliable in patients with pre-existing neurological disease, encephalopathy, or abnormal baseline EEG.
   • Interindividual variability - some patients are unresponsive at BIS values within the "normal anaesthesia" range and vice versa.
6. Lag time - the algorithm smooths/averages EEG data over roughly 15-30 seconds, producing a delay between an actual change in anaesthetic depth and the displayed BIS value, limiting its use in detecting sudden events.
7. Only measures cortical activity - it does not assess subcortical, brainstem, or spinal cord function, so it cannot detect purely reflex/spinal movement responses to surgical stimulation, and does not reliably detect cerebral ischaemia below the cortex.
8. Does not measure or guarantee amnesia or analgesia - a normal BIS does not exclude implicit memory formation, and it gives no information on the adequacy of pain control (a separate concern from hypnotic depth).
9. Signal quality dependent - accurate electrode placement, good skin contact, and adequate signal quality index (SQI) are required; poor electrode contact gives unreliable numbers without clear warning in some circumstances.
10. Cost and single-use sensor - added expense per case; not universally available in resource-limited settings.
11. No proven mortality/major-morbidity benefit - despite widespread use, large trials have not consistently demonstrated improved patient-oriented outcomes (mortality, major morbidity) compared with standard clinical monitoring plus MAC-based dosing, other than a reduction in awareness incidence in some at-risk cohorts and possibly faster emergence.

Practical Points / Exam Tips

• BIS is an adjunct, not a replacement, for clinical assessment of anaesthetic depth (heart rate, blood pressure, lacrimation, sweating, pupil size, movement) and must always be interpreted alongside end-tidal anaesthetic agent concentration.
• Current guidance (e.g., NICE in the UK, and reflected across anaesthesia texts) recommends considering BIS/processed EEG monitoring specifically in patients on TIVA with neuromuscular blockade and in those at higher risk of awareness, rather than as a routine monitor for all general anaesthetics - consistent with the textbook statement that such monitors are "recommended in patients at greater risk of awareness and in patients receiving TIVA... data on effectiveness remains mixed and such devices should be used along with clinical observation" (Scott-Brown's Otorhinolaryngology, p. 391).

Summary Table

Recent evidence note